Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2016-07-727891 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Candida Epiglottitis in a Patient Undergoing Chemotherapy for Small Cell Lung Cancer: A Case Report.
Cureus
October 2024
Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Epiglottitis is a critical infection that can result in upper airway obstruction. While bacterial infections are the most common cause of acute epiglottitis, Candida epiglottitis remains relatively rare. We report a case involving an 82-year-old male undergoing chemotherapy for small cell lung cancer.
View Article and Find Full Text PDF[Investigation of the Changes in Blood Cell Components following the Administration of Pegfilgrastim in Neo-Adjuvant and Adjuvant FEC Chemotherapy for Breast Cancer].
Gan To Kagaku Ryoho
September 2024
Dept. of Pharmacy, The Cancer Institute Hospital.
Article Synopsis
- Perioperative FEC therapy is a common treatment for breast cancer, but over 20% of patients experience febrile neutropenia (FN), which pegfilgrastim is often used to prevent.
- A study on pegfilgrastim's long-term safety found no significant differences in blood cell counts or long-term effects after one year of use.
- Pegfilgrastim administration significantly reduced the incidence of FN (6.5% with pegfilgrastim vs. 22.8% without), indicating it can be safely used for one year in breast cancer patients undergoing chemotherapy.
Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.
PLoS One
June 2024
Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States of America.
Article Synopsis
- This study analyzes the effects of biosimilars on the pricing of eight biologic drugs in 57 countries from 2012 to 2019 using sales data.
- The entry of biosimilars led to immediate price reductions of several biologics, with significant annual decreases persisting over time.
- The findings highlight the role of biosimilars in lowering drug costs globally, suggesting that enhancing biosimilar availability could help control healthcare expenditures related to biologics.
Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
Drug Saf
December 2023
Sandoz Inc, Princeton, NJ, USA.
Article Synopsis
- Biosimilars are approved treatment options based on comparisons to reference biologics, but concerns about their long-term safety remain, prompting a review of data from eight Sandoz biosimilars over up to 18 years.
- Cumulative exposure data showed over 1.3 billion patient treatment days for seven biosimilars and 1.8 million doses for one, indicating significant real-world use.
- The analysis concluded that the overall benefit-risk profiles of these Sandoz biosimilars are favorable and consistent with their reference biologics.
Delayed renal injury in survivors of hematologic acute radiation syndrome.
Int J Radiat Biol
June 2023
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Article Synopsis
- - The study addresses the public health concern of mass casualty disasters involving radiation, noting that survivors of high radiation exposure (8-10 Gy) face delayed health issues, particularly renal failure.
- - Researchers established the WAG/RijCmcr rat model to test medical countermeasures (MCM) for acute hematologic radiation syndrome (H-ARS) and found that the FDA-approved drug pegfilgrastim significantly improved survival rates in rats post-exposure.
- - Findings indicated that while peg-GCSF treatment enhanced short-term survival, survivors of higher TBI doses experienced a notable decline in long-term survival and renal function, highlighting the need for ongoing monitoring and care for these individuals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!